Cancer Care Ontario | Cancer Care Ontario

496 Results

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Status: Current
ID: PET 2023-1

Nov 2023

Regimen

Cancer Type:

Hematologic,

Multiple Myeloma

Show More Show more tags

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Dec 2023

Guidelines and Advice

Status: Current
ID: 8-7
Version: 2

Mar 2023

Guidelines and Advice

Status: In-Review
ID: GL END 7-13-2
Version: 2

Nov 2019